Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Decision on EU marketing authorisation for this population expected by September 2024
Campaign launched to spread awareness regarding dengue prevention and control
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Subscribe To Our Newsletter & Stay Updated
